Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2017 | Pages:
104 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) - Pipeline Review, H1 2017 Summary According to the recently published report 'Poly [ADP Ribose] Polymerase 2 - Pipeline Review, H1 2017'; Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) pipeline Target constitutes close to 18 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes. Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) - Poly [ADP-ribose] polymerase 2 is an enzyme encoded by the PARP2 gene. It is involved in the base excision repair (BER) pathway, by catalyzing the poly (ADP-ribosylation) of a limited number of acceptor proteins involved in chromatin architecture and in DNA metabolism. This modification follows DNA damages and appears as an obligatory step in signaling pathway leading to the reparation of DNA strand breaks. The report 'Poly [ADP Ribose] Polymerase 2 - Pipeline Review, H1 2017' outlays comprehensive information on the Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities. It also reviews key players involved in Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 1, 2, 8, 1 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology which include indications Breast Cancer, Ovarian Cancer, Solid Tumor, Fallopian Tube Cancer, Metastatic Breast Cancer, Small-Cell Lung Cancer, Gastric Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Peritoneal Cancer, Epithelial Ovarian Cancer, Metastatic Pancreatic Cancer, Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, Non-Small Cell Lung Cancer, Adenocarcinoma Of The Gastroesophageal Junction, B-Cell Chronic Lymphocytic Leukemia, Endometrial Cancer, Esophageal Cancer, Ewing Sarcoma, Follicular Lymphoma, Glioblastoma Multiforme (GBM), Head And Neck Cancer Squamous Cell Carcinoma, Laryngeal Cancer, Leiomyosarcoma, Lung Cancer, Malignant Mesothelioma, Melanoma, Metastatic Colorectal Cancer, Metastatic Melanoma, Metastatic Ovarian Cancer, Metastatic Prostate Cancer, Neuroendocrine Tumors, Non-Hodgkin Lymphoma, Oropharyngeal Cancer, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Peritoneal Tumor, Prostate Cancer, Rectal Cancer, Recurrent Glioblastoma Multiforme (GBM), Soft Tissue Sarcoma and Testicular Cancer. Scope - The report provides a snapshot of the global therapeutic landscape for Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) - The report reviews Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30)targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30)targeted therapeutics and enlists all their major and minor projects - The report assesses Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) targeted therapeutics Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30)development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) - Overview Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Products under Development by Universities/Institutes Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) - Companies Involved in Therapeutics Development AbbVie Inc AstraZeneca Plc BeiGene Ltd Clovis Oncology Inc Eisai Co Ltd Ildong Pharmaceutical Co Ltd Jiangsu Hengrui Medicine Co Ltd Shanghai Acebright Pharmaceuticals Group Co Ltd Tesaro Inc Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) - Drug Profiles ABT-767 - Drug Profile Product Description Mechanism Of Action R&D Progress AZ-0108 - Drug Profile Product Description Mechanism Of Action R&D Progress AZD-1775 + olaparib - Drug Profile Product Description Mechanism Of Action R&D Progress AZD-6738 + olaparib - Drug Profile Product Description Mechanism Of Action R&D Progress BGB-290 - Drug Profile Product Description Mechanism Of Action R&D Progress BGBA-317 + BGB-290 - Drug Profile Product Description Mechanism Of Action R&D Progress CK-102 - Drug Profile Product Description Mechanism Of Action R&D Progress E-7449 - Drug Profile Product Description Mechanism Of Action R&D Progress niraparib - Drug Profile Product Description Mechanism Of Action R&D Progress NOV-1401 - Drug Profile Product Description Mechanism Of Action R&D Progress olaparib - Drug Profile Product Description Mechanism Of Action R&D Progress rucaparib camsylate - Drug Profile Product Description Mechanism Of Action R&D Progress SC-10914 - Drug Profile Product Description Mechanism Of Action R&D Progress SHR-3162 - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Target PARP1, 2, 3 and NO for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress SOMCL-9112 - Drug Profile Product Description Mechanism Of Action R&D Progress veliparib - Drug Profile Product Description Mechanism Of Action R&D Progress YHP-743 - Drug Profile Product Description Mechanism Of Action R&D Progress Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) - Dormant Products Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) - Discontinued Products Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) - Product Development Milestones Featured News & Press Releases May 23, 2017: Clovis Oncology Announces Presentations at 2017 ASCO Annual Meeting May 12, 2017: McKesson Specialty Health Selected by TESARO to provide ZEJULA (niraparib), Approved for the Treatment of Recurrent Ovarian Cancer May 11, 2017: TESARO Partners With Clinigen to Initiate European Managed Access Program for Niraparib in Patients With Recurrent Ovarian Cancer Apr 24, 2017: Biologics Selected by TESARO as a Specialty Pharmacy Provider for ZEJULATM (niraparib), Approved for the Treatment of Recurrent Ovarian Cancer Apr 21, 2017: BeiGene Announces Presentation on a Phase I Study of PD-1 Antibody BGB-A317 in Combination with PARP Inhibitor BGB-290 at the 2017 American Society of Clinical Oncology Annual Meeting Apr 19, 2017: Diplomat Will Dispense ZEJULA to Treat Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Apr 19, 2017: TESARO Announces Availability of Zejula (Niraparib) for Patients With Recurrent Ovarian Cancer in the U.S. Apr 19, 2017: US Bioservices selected by TESARO to dispense ZEJULA Apr 19, 2017: AbbVie Announces Topline Results from Two Phase 3 Studies Investigating Veliparib in Combination with Chemotherapy for the Treatment of Patients with Advanced or Metastatic Squamous Non-Small Cell Lung Cancer and Early-Stage Triple-Negative Breast Cancer Mar 28, 2017: AstraZeneca shares progress on LYNPARZA (olaparib) tablets in the US Mar 28, 2017: Clovis Oncology Announces Data Presentations At AACR Annual Meeting 2017 Mar 28, 2017: Eisai to Present Data on E7449 at 2017 AACR Annual Meeting Mar 27, 2017: TESARO Announces Expanded Development Program for Niraparib Focused on the Treatment of Front-Line Metastatic Ovarian and Lung Cancers and Metastatic Breast Cancer Mar 27, 2017: Tesaro Announces U.S. FDA Approval Of Zejula (Niraparib) For Women With Recurrent Ovarian Cancer Mar 14, 2017: Lynparza Phase III SOLO-2 data demonstrate progression-free survival benefit in BRCA-mutated ovarian cancer as maintenance therapy Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H1 2017 Number of Products under Development by Therapy Areas, H1 2017 Number of Products under Development by Indications, H1 2017 Number of Products under Development by Indications, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Indications, H1 2017 (Contd..2), H1 2017 Number of Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Products under Development by Companies, H1 2017 (Contd..3), H1 2017 Products under Development by Companies, H1 2017 (Contd..4), H1 2017 Products under Development by Companies, H1 2017 (Contd..5), H1 2017 Number of Products under Investigation by Universities/Institutes, H1 2017 Products under Investigation by Universities/Institutes, H1 2017 Number of Products by Stage and Mechanism of Actions, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Pipeline by AbbVie Inc, H1 2017 Pipeline by AstraZeneca Plc, H1 2017 Pipeline by BeiGene Ltd, H1 2017 Pipeline by Clovis Oncology Inc, H1 2017 Pipeline by Eisai Co Ltd, H1 2017 Pipeline by Ildong Pharmaceutical Co Ltd, H1 2017 Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017 Pipeline by Shanghai Acebright Pharmaceuticals Group Co Ltd, H1 2017 Pipeline by Tesaro Inc, H1 2017 Dormant Projects, H1 2017 Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
